Investigation reveals Swiss medical providers billing outsourced services at Swiss rates despite lower foreign costs, prompting potential legal changes.

"In principle, services are only reimbursed if they are done in Switzerland and by a service provider authorised to practise in Switzerland"
"Invoices only show the name of the hospital or doctor's surgery, and you can't see where the service was provided"
A significant controversy has emerged in the Swiss healthcare sector as investigations reveal that medical services performed abroad are being billed at Swiss rates, despite substantially lower operational costs in foreign countries. This practice has sparked debate about transparency, cost efficiency, and the integrity of Switzerland's healthcare billing system.
Major Swiss healthcare providers, including the Hirslanden group with its 17 hospitals, have established extensive outsourcing networks. Medical imaging services such as MRIs, X-rays, and other diagnostic scans are being analyzed in countries like France, Germany, and Hungary. Similarly, Medgate, Switzerland's leading telemedicine provider, employs doctors in multiple European countries, including Germany and Spain, with plans to expand to France and Italy.
The Federal Office of Public Health (FOPH) maintains that medical services should typically only be reimbursed when performed in Switzerland by authorized Swiss practitioners. However, the current regulatory framework contains significant grey areas, particularly regarding telemedicine. Santésuisse, the Swiss health insurers' umbrella organization, has expressed concerns about the lack of transparency in billing practices, as invoices don't clearly indicate where services are actually performed.
Recent developments suggest a shifting landscape in Swiss healthcare regulation. Swiss parliamentarians have voted to allow reimbursement of medical services provided abroad, potentially leading to significant legal changes. This decision could reshape the healthcare sector's operational model and cost structure, while raising questions about quality control and patient care standards. The industry awaits clear guidelines to address current ambiguities and ensure fair pricing practices.